Lexicon Pharmaceuticals to Present at Bio InvestorForum
October 04 2007 - 4:00PM
PR Newswire (US)
THE WOODLANDS, Texas, Oct. 4 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Arthur T.
Sands, M.D., Ph.D., Lexicon's president and chief executive
officer, will present at the BIO InvestorForum at The Palace Hotel
in San Francisco, California on Thursday, October 11, 2007 at 11:00
a.m. Pacific Time. A live webcast of Lexicon's presentation may be
accessed on its corporate website at http://www.lexpharma.com/. An
archived version of the webcast will be available on the website
through October 19, 2007. About Lexicon Lexicon is a
biopharmaceutical company focused on the discovery and development
of breakthrough treatments for human disease. Lexicon currently has
clinical programs underway for such areas of major unmet medical
need as irritable bowel syndrome and cognitive disorders. The
company has used its proprietary gene knockout technology to
discover more than 100 promising drug targets and create an
extensive pipeline of clinical and preclinical programs in the
therapeutic areas of diabetes and obesity, cardiovascular disease,
psychiatric and neurological disorders, cancer, immune system
disorders and ophthalmic disease. To advance the development and
commercialization of its programs, Lexicon is working both
independently and through collaborators including Bristol-Myers
Squibb Company, Genentech, Inc. and N.V. Organon. For additional
information about Lexicon and its programs, please visit
http://www.lexpharma.com/. Safe Harbor Statement This press release
contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Arti Allam, Corporate Communications
Associate of Lexicon Pharmaceuticals, Inc., +1-281-863-3738, Web
site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024